ReviewInternational urology and nephrology2026
Nephrology 2050: an evidence-informed roadmap from precision prevention to kidney regeneration.
Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is projected to become one of the leading causes of premature mortality worldwide by 2050. Simultaneously, advances in CKM medicine, artificial intelligence (AI), molecular biology, and regenerative science are transforming nephrology from a reactive specialty focused on kidney failure into one centered on lifelong kidney health preservation. RECENT
findingsThis review synthesizes contemporary evidence describing four converging revolutions that are reshaping kidney medicine: precision prevention, digital and precision nephrology, advanced kidney replacement, and regenerative kidney medicine. Disease-modifying therapies, albuminuria-first strategies, AI-enabled risk prediction, multi-omics profiling, wearable biosensors, and digital twins are enabling earlier diagnosis and personalized intervention. In parallel, genetically engineered pig kidney xenotransplantation, bioengineered kidneys, and implantable artificial kidneys are redefining future kidney replacement by addressing the limitations of conventional dialysis and transplantation. FUTURE PERSPECTIVES: Rather than representing competing innovations, these technologies are expected to function as an integrated kidney health ecosystem, combining continuous risk assessment, precision therapeutics, regenerative biology, and individualized organ replacement. Successful implementation will require equitable access, sustainable healthcare systems, adaptive regulatory frameworks, and a digitally competent nephrology workforce.
conclusionsThe future of nephrology will be defined not by a single disruptive innovation, but by the convergence of prevention, precision medicine, digital health, regenerative biology, and advanced kidney replacement technologies. By 2050, the greatest achievement of nephrology may not be replacing the failing kidney, but preventing kidney failure while preserving lifelong kidney health.
Indexed as
Identifiers
42611122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.